Weekly FDA Drug Pipeline Calendar (Oct 17- Oct 21)

BioPharm Insight US wrote a column · Oct 17, 2022 05:36

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.

Top Medical News of the Week

Moderna and Merck to develop a cancer vaccine for high-risk melanoma patients

Last week, we had some exciting news on cancer vaccine development announced by Moderna and Merck.

Moderna's vaccine, based on its messenger RNA technology, is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer, in a phase two trial. The companies expect to report data in the fourth quarter of this year.

Omicron BA.5 is declining in the U.S. as emerging variants gain ground, CDC data shows

The U.S. faces at least seven different versions of Covid-19 omicron as the nation heads into winter when health officials are expecting another wave of viral infections.

Abbott has a new glucose monitor for diabetics — It's so small

$Abbott Laboratories(ABT.US)$ and $DexCom(DXCM.US)$ are the leaders in the CGM market, which hit $5.1 billion in revenue in 2021 and is expected to reach $13.2 billion by 2028, according to Vantage Market Research. Abbott's CGM systems, called FreeStyle Libre, generated $3.7 billion in revenue last year, with 4 million users globally.

Abbott has just released its newest CGM, the FreeStyle Libre 3. It comes with an important upgrade. Whereas the previous systems were "flash" CGMs, which means you had to hold your reader or phone close to the sensor to get a reading, the new version sends data straight to your phone.